NADPH oxidase inhibitor regulates microRNAs with improved outcome after mechanical reperfusion.
BACKGROUND
Inhibition of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) pathway improves the neurological outcome in the transient middle cerebral artery occlusion (tMCAO) animal model. In this study we analyzed the microRNAs profile targeting NOX2 and NOX4 genes and its response to NOX2/4 inhibitor VAS2870 to understand the mechanisms of this protective effect.


METHODS
The intraluminal filament tMCAO model was established in hyperglycemic rats (n=106) with 5 hours ischemia followed by 19 hours reperfusion. NOX inhibitor VAS2870 was delivered intravenously before reperfusion. Infarct volume, hemorrhagic transformation, and mortality were determined at 24 hours after cerebral ischemia. MicroRNAs profile targeting NOX2 and NOX4 genes were predicted by microRNA databases and further evaluated by microRNA microarray and quantitative RT-PCR.


RESULTS
Ten microRNAs potentially targeting NOX2 and NOX4 genes (including microRNA-29a, microRNA-29c, microRNA-126a, microRNA-132, microRNA-136, microRNA-138, microRNA-139, microRNA-153, microRNA-337, and microRNA-376a) were significantly downregulated in the ischemic hemisphere in the tMCAO group compared with the sham-operated group, as shown by microRNA microarray and quantitative RT-PCR (all p<0.05). Intravenous treatment with NOX inhibitor VAS2870 before reperfusion increased the expression of microRNA-29a, microRNA-29c, microRNA-126a, and microRNA-132 compared with the tMCAO group (all p<0.05).


CONCLUSIONS
Several microRNAs potentially targeting NOX2 and NOX4 genes displayed altered levels in hyperglycemic rats with the tMCAO model, suggesting their regulatory roles and targeting potentials for acute ischemic stroke treatment. Targeting specific microRNAs may represent a novel intervention opportunity to improve outcome and reduce hemorrhagic transformation after mechanical reperfusion for acute ischemic stroke.
Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Zhong
Z
Liu
Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yong-Hua
YH
Tuo
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Jian-Wen
JW
Chen
Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Qing-Yuan
QY
Wang
The Institute of Life Sciences, Wenzhou University, Wenzhou, China.
Songlin
S
Li
Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Ming-Chang
MC
Li
Key Laboratory on Assisted Circulation of Ministry of Health, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Gang
G
Dai
Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jin-Shan
JS
Wang
Department of Biology, Guangdong Pharmaceutical University, Guangzhou, China.
Yong-Li
YL
Zhang
Division of Interventional Neuroradiology, Kaiser Permanente Medical Center, Los Angeles, California, USA.
Lei
L
Feng
Department of Neurosurgery, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.|Guangdong Province Key Laboratory of Brain Function and Disease, Sun Yat-sen University, Guangzhou, China.
Zhong-Song
ZS
Shi
D000818:Animals; D001583:Benzoxazoles / Q000494:pharmacology* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000188:drug therapy / Q000201:enzymology; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D035683:MicroRNAs / Q000502:physiology*; D019255:NADPH Oxidases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion / Q000379:methods*; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology* / Q000627:therapeutic use
C511179:3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine; D001583:Benzoxazoles; D035683:MicroRNAs; D014230:Triazoles; D019255:NADPH Oxidases
Hemorrhage; Stroke; Thrombectomy